Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $66.87 million. The enterprise value is -$7.92 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 162.67 million shares outstanding. The number of shares has increased by 21.50% in one year.
| Current Share Class | 162.67M |
| Shares Outstanding | 162.67M |
| Shares Change (YoY) | +21.50% |
| Shares Change (QoQ) | +27.15% |
| Owned by Insiders (%) | 0.67% |
| Owned by Institutions (%) | 20.92% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.68, with a Debt / Equity ratio of 0.11.
| Current Ratio | 6.68 |
| Quick Ratio | 6.23 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -76.21% and return on invested capital (ROIC) is -45.44%.
| Return on Equity (ROE) | -76.21% |
| Return on Assets (ROA) | -41.71% |
| Return on Invested Capital (ROIC) | -45.44% |
| Return on Capital Employed (ROCE) | -84.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.09M |
| Employee Count | 97 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.21% in the last 52 weeks. The beta is 3.00, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 3.00 |
| 52-Week Price Change | -90.21% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 1.70 |
| Relative Strength Index (RSI) | 34.54 |
| Average Volume (20 Days) | 1,966,393 |
Short Selling Information
The latest short interest is 8.73 million, so 5.36% of the outstanding shares have been sold short.
| Short Interest | 8.73M |
| Short Previous Month | 8.77M |
| Short % of Shares Out | 5.36% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -109.72M |
| Pretax Income | n/a |
| Net Income | -105.77M |
| EBITDA | -100.75M |
| EBIT | -109.72M |
| Earnings Per Share (EPS) | -$1.15 |
Full Income StatementBalance Sheet
The company has $88.16 million in cash and $12.91 million in debt, giving a net cash position of $75.25 million or $0.46 per share.
| Cash & Cash Equivalents | 88.16M |
| Total Debt | 12.91M |
| Net Cash | 75.25M |
| Net Cash Per Share | $0.46 |
| Equity (Book Value) | 119.40M |
| Book Value Per Share | 0.73 |
| Working Capital | 80.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$84.95 million and capital expenditures -$844,000, giving a free cash flow of -$85.80 million.
| Operating Cash Flow | -84.95M |
| Capital Expenditures | -844,000 |
| Free Cash Flow | -85.80M |
| FCF Per Share | -$0.53 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |